A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR
Manuscript Number:
18-0749R1
Author(s):
Jeffrey L. Gunter, Clifford R. Jack Jr., David S. Knopman, Val J. Lowe, Ronald C. Petersen, Christopher G. Schwarz, Matthew L. Senjem, Prashanthi Vemuri, Stephen D. Weigand
Disclosures
Jeffrey L. Gunter
Nothing to Disclose
Clifford R. Jack Jr.
Nothing to Disclose
David S. Knopman
Consulting Fees:
DSMB for DIAN-TU study
Grants
Agency:
Lilly, A4 study study site
Dates:
2014 to 2022
Agency:
Biogen aducanumab study site
Dates:
2016 to 2020
Val J. Lowe
Grants
Agency:
GE Heathcare
Dates:
2004-2017
Agency:
Siemens Molecular Imaging
Dates:
2007-2016
Agency:
AVID Radiopharmaceuiticals
Dates:
2010- present
Ronald C. Petersen
Consulting Fees:
Consultant for the following:
Hoffman-La Roche, Inc.
Merck, Inc.
Genentech, Inc.
Biogen, Inc.
Lecture Fees:
Presentation for GE Healthcare; $4800 for moderating a debate.
Patents/Royalties
Yes, royalties for book: “Mild Cognitive Impairment,” Oxford University Press, 2003
Christopher G. Schwarz
Nothing to Disclose
Matthew L. Senjem
Equity:
Disclosures outside the submitted work: M.L.S. owns stocks in Align Technology, Inc., CRISPR Therapeutics, Ionis Pharmaceuticals, Johnson & Johnson, LHC Group, Inc., Medtronic, Inc., Mesa Laboratories, Inc., Natus Medical Inc., and Varex Imaging Corporation.
MLS has owned these medical related stocks within the past three years, unrelated to the current work: Gilead Sciences, Inc., Globus Medical Inc., Inovio Biomedical Corp., Oncothyreon, Inc., Parexel International Corporation